@article{3599d050dc9d40e28bfd43ff1fd93c94,
title = "Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging",
abstract = "Background Inexpensive, non-invasive tools for assessing Alzheimer-type pathophysiologies are needed. Computerized cognitive assessments are prime candidates. Methods Cognitively normal participants, aged 51-71, with magnetic resonance imaging, fluorodeoxyglucose-positron emission tomography (FDG-PET), amyloid PET, CogState computerized cognitive assessment, and standard neuropsychological tests were included. We first examined the association between the CogState battery and neuroimaging measures. We then compared that association to the one between standard neuropsychological z-scores and neuroimaging. Results Slower reaction times for CogState Identification and One Back, and lower memory and attention z-scores, were associated (P <.05) with FDG-PET hypometabolism. Slower time on the Groton Maze Learning Task and worse One Card Learning accuracy were associated (P <.05) with smaller hippocampal volumes. There were no associations with amyloid PET. Associations of CogState and neuropsychological Z-scores with neuroimaging were small and of a similar magnitude. Conclusions CogState subtests were cross-sectionally comparable to standard neuropsychological tests in their relatively weak associations with neurodegeneration imaging markers.",
keywords = "Amyloidbeta, Computerized cognitive battery, Hippocampal volume, Neuroimaging, Neuropsychology, Preclinical Alzheimer's disease",
author = "Mielke, {Michelle M.} and Weigand, {Stephen D.} and Wiste, {Heather J.} and Prashanthi Vemuri and MacHulda, {Mary M.} and Knopman, {Davis S.} and Val Lowe and Roberts, {Rosebud O.} and Kejal Kantarci and Rocca, {Walter A.} and Jack, {Clifford R.} and Petersen, {Ronald C.}",
note = "Funding Information: Mr. Weigand reports no disclosures. Ms. Wiste reports no disclosures. Dr. Vemuri receives support from the NIH/NIA (R01 AG041851, R01 AG011378) and the Alzheimer's Association . Dr. Machulda reports no disclosures. Dr. Knopman serves as Deputy Editor for Neurology {\textregistered} ; served on a Data Safety Monitoring Board for Lilly Pharmaceuticals; served as a consultant to TauRx Pharmaceuticals, was an investigator in clinical trials sponsored by Baxter, Elan Pharmaceuticals, and Forest Pharmaceuticals in the past 2 years; and receives research support from the NIH (U01 AG006786, P50 AG016574, R01 AG016574, R01 AG011378). Dr. Lowe serves on scientific advisory boards for Bayer Schering Pharma and GE Healthcare and receives research support from GE Healthcare , Siemens Molecular Imaging , AVID Radiopharmaceuticals , the NIH (U01 AG006786, P50 AG016574, R01 AG041851, R01 AG011378), the MN Partnership for Biotechnology and Medical Genomics , and the Leukemia and Lymphoma Society . Dr. Roberts receives research support from the NIH/NIA (U01 AG006786) and from Abbvie Health Economics and Outcomes Research . Dr. Kantarci serves on the data safety monitoring board for Pfizer Inc. and Jansen Alzheimer's Immunotherapy, Takeda Global Research & Development Center, Inc.; and she is funded by the NIH [ R01AG040042 , P50 AG16574/P1 , P50 AG44170/P 2 ]. Dr. Rocca receives research support from the NIH (U01 AG006786, R01 AG034676) and the Michael J. Fox Foundation . Dr. Jack provides consulting services for Janssen Research & Development, LLC. He receives research funding from the National Institutes of Health ( R01 AG011378 , R01 AG041851 , R01 AG037551 , U01 HL096917 , U01 AG032438 , U01 AG024904 ), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation . Funding Information: This study was supported by funding from the National Institutes of Health/National Institute on Aging P50 AG016574 , U01 AG006786 , R01 AG041851 , and R01 AG011378 ; the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, the Driskill Foundation , and was made possible by the Rochester Epidemiology Project (R01 AG034676). The funding organizations did not have a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2014 The Alzheimer's Association. All rights reserved.",
year = "2014",
month = nov,
day = "1",
doi = "10.1016/j.jalz.2014.09.001",
language = "English (US)",
volume = "10",
pages = "779--789",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "6",
}